Boston Scientific Corporation (NYSE:BSX) Given Average Recommendation of “Moderate Buy” by Analysts

Boston Scientific Corporation (NYSE:BSX) has earned an average rating of “Moderate Buy” from the thirty-one brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation and twenty-four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $71.6154.

Several equities analysts have commented on the company. Royal Bank Of Canada lowered their price objective on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, July 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a research report on Friday, June 12th. BTIG Research decreased their price target on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, July 29th. Oppenheimer dropped their price objective on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday, July 27th. Finally, Needham & Company LLC cut their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th.

Boston Scientific Stock Performance

Shares of BSX opened at $51.46 on Tuesday. The company has a 50-day simple moving average of $46.12 and a two-hundred day simple moving average of $58.81. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The firm has a market capitalization of $74.58 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56. Boston Scientific has a one year low of $42.20 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts anticipate that Boston Scientific will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Cheryl Pegus bought 1,770 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 202,122 shares of company stock worth $9,813,931. 0.34% of the stock is currently owned by corporate insiders.

Institutional Trading of Boston Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of BSX. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter valued at approximately $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific in the 4th quarter worth approximately $26,000. Sfam LLC purchased a new position in Boston Scientific in the 4th quarter worth approximately $29,000. Finally, Eagle Bay Advisors LLC bought a new position in Boston Scientific in the 4th quarter valued at approximately $30,000. 89.07% of the stock is currently owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.